{"id":"NCT02794285","sponsor":"AstraZeneca","briefTitle":"Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus","officialTitle":"A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06-30","primaryCompletion":"2021-12-21","completion":"2021-12-21","firstPosted":"2016-06-09","resultsPosted":"2023-01-13","lastUpdate":"2023-01-13"},"enrollment":559,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Active Systemic Lupus Erythematosus"],"interventions":[{"type":"BIOLOGICAL","name":"Anifrolumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Anifrolumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to characterise long-term safety and tolerability of intravenous anifrolumab.","primaryOutcome":{"measure":"Exposure-adjusted Incidence Rates (EAIRs) of Adverse Events of Special Interest (AESIs)","timeFrame":"Up to a maximum of 1114 days","effectByArm":[{"arm":"Randomised Anifrolumab 300 mg","deltaMin":11,"sd":null},{"arm":"Placebo Feeder + Placebo LTE","deltaMin":9.6,"sd":null},{"arm":"Placebo Feeder + Anifrolumab 300 mg LTE","deltaMin":12.9,"sd":null},{"arm":"Anifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE","deltaMin":12.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":175,"countries":["United States","Argentina","Australia","Bulgaria","Canada","Chile","Colombia","France","Germany","Hungary","Israel","Japan","Lithuania","Mexico","Peru","Poland","Romania","Russia","South Africa","South Korea","Spain","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["40324450","37706527","36369793"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3461C00009&amp;attachmentIdentifier=ab5090f5-1f24-42c2-b969-8f0316da65a5&amp;fileName=D3461C00009_CSR_Synopsis_Redacted_pdfa.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":56,"n":257},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Urinary tract infection","Bronchitis","Headache"]}}